Source comparison
Best BPC-157 Dosage for Wound Healing: Protocol Comparison
Acute Soft Tissue Injury 250–350 mcg Twice daily (12-hour intervals) Subcutaneous, 2–5 cm from injury Muscle, ligament, tendon First 7–10 days post-injury; targets inflammation modulation Chronic Tendinopathy 300–500 mcg Twice daily Subcutaneous near affected
This comparison does not assign a generated winner or score.
- Acute Soft Tissue Injury
- 250–350 mcg
- Twice daily (12-hour intervals)
- Subcutaneous, 2–5 cm from injury
- Muscle, ligament, tendon
- First 7–10 days post-injury; targets inflammation modulation
- Chronic Tendinopathy
- 300–500 mcg
- Twice daily
- Subcutaneous near affected tendon
- Tendon (Achilles, rotator cuff, patellar)
- Ongoing repair during proliferative phase; minimum 4–6 weeks
- Surgical Wound Healing
- 250–400 mcg
- Subcutaneous along incision margin
- Dermal and subdermal tissue
- Initiated 24–48 hours post-op; continued 14–21 days
- Gastric Ulcer Repair
- 200–300 mcg
- Once daily
- Subcutaneous abdominal
- Gastric mucosa
- Oral administration shows poor bioavailability; subcutaneous preferred
- Bone Fracture Adjunct
- 350–500 mcg
- Subcutaneous near fracture site
- Bone, periosteum
- Used alongside standard immobilization; enhances callus formation
- Professional Assessment
- 250–500 mcg split dosing is the evidence-backed range. Higher doses do not proportionally improve outcomes and may increase injection site reactions. Proximity to injury site is more critical than total daily dose.